



SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

Group Whistleblowing Procedure as part of the
SGD Pharma Group's activities

Global Application

August 2026

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

The purpose of this procedure is to explain how the whistle-blowing within the SGD Pharma Group (hereinafter the "Procedure") works.

It also informs whistleblowers of the possibility of launching an external alert independently of any internal alert, and lists the competent authorities who can then be contacted. The implementation of this internal whistleblowing Procedure meets the requirements of the European directive 2019/1937 of October 23, 2019, the French law ("**Waserman Act**" of March 21, 2022), the German Whistleblowers Protection Act ("**HinSchG**") and the applicable Indian legislation on vigil mechanism ("**Companies Act**", 2013 and respective "**Companies Rules**", 2014).

This legal framework aims to protect whistleblowers but also any facilitators, who ease their action, and any person directly linked to the whistle-blowers, who may suffer from retaliation measures.

This Procedure is part of the information and prevention approach encouraged by the Code of Ethics and Conduct already in place within the SGD Pharma Group.

1. The purpose of the whistleblowing Procedure

Use of this Procedure is optional. Refraining from using the whistleblowing Procedure does not entail any consequences for the employee.

This Procedure does not replace any other alert rights that may be in place at the SGD Pharma Group sites/companies. In particular, the whistleblowing Procedure or the right to alert, already provided for in the Internal Regulations of each establishment/company, used by an employee when he or she has reasonable cause to believe that a work situation presents a serious and imminent danger to his or her life or health, enabling him or her to withdraw from his or her work position.

The whistleblowing Procedure must be triggered in compliance with the applicable laws and regulations, and in accordance with the procedures set out below.

2. Scope of application

The SGD Pharma Group recognizes the right of any person to report facts of which he or she has personal knowledge or of which he or she has knowledge in the course of his or her professional activities within the Group.

Pursuant to European directive 2019/1937 of October 23, 2019, whistleblower is a natural person who reports or discloses information about violations which he or she obtained in connection with his or her professional activity or in the run-up to a professional activity relating to:

- ✓ *a criminal offense ("crime" or "délit")*
- ✓ *a violation or attempt to conceal a violation of an international commitment regularly ratified or approved,*

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

- ✓ *administrative offences as far as the violated law aims to protect life, limb or health or the protection of the rights of workers or their representative bodies*
- ✓ *violations of federal and state legal provisions and directly applicable legal acts of the European Union with requirements, inter alia, on*
 - *product safety and conformity,*
 - *environmental protection,*
 - *data protection law,*
 - *quality and safety standards for medical devices,*
- ✓ *a violation or attempt to conceal a violation of a unilateral act of an international organization taken on the basis of an international commitment regularly ratified or approved.*

By way of example, this may include the following facts:

- ✓ **Corruption and financial irregularities;** *for example, bribery, unfair competition, money laundering, fraud, conflict of interest.*
- ✓ **Violations of health and safety and labor code provisions;** *for example, workplace health and safety, product safety, serious discrimination and harassment, all of which contravene the law.*
- ✓ **Environmental violations,** *e.g. illegal handling of hazardous waste.*
- ✓ **Violations of privacy;** *for example, misuse of personal data.*

3. The alert issuer

Pursuant to applicable European and national regulations, the whistleblower (the "Alert Issuer") must be:

- ✓ *Employee or former employee of the company when the information was obtained within the framework of this relationship.*
- ✓ *Who applied for a job with the company when the information was obtained as part of this application.*
- ✓ *Shareholder, associate, holder of voting rights at the company's general meeting.*
- ✓ *Member of the company's administrative, management or supervisory body.*
- ✓ *External or occasional employee of the company.*
- ✓ *Co-contractor of the company.*
- ✓ *Company subcontractor.*
- ✓ *Member of the administrative, management or supervisory body of a co-contractor or subcontractor*
- ✓ *Employee of one of the company's co-contractors or subcontractors.*

The alert is made either in person, in writing or by voice mail, anonymously or not, at the option of the Alert Issuer.

The Alert Issuer's identity remains confidential.

This right to alert must be exercised in good faith. No employee may experience reprisals or disadvantages from SGD for having initiated a whistle-blowing procedure based on facts that

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

he or she believed in good faith to be true and accurate. Under these conditions, the Alert Issuer will not be sanctioned by SGD if, at the end of the investigation, it turns out that the facts reported are not illicit or do not lead to a sanction or remediation.

Conversely, an employee who issues a warning in bad faith, i.e. in the knowledge of the inaccuracy of the facts he or she is reporting, is liable to disciplinary action (see Internal Regulations) and legal proceedings.

4. Informing those affected by the alert

Any person, with or without an employment contract with an SGD Pharma Group entity, is liable to be the subject of an alert.

Except in cases where this could lead to the deletion of evidence, a leak, etc., the person concerned by the alert is informed of the existence of an alert in which he or she is named, in order to inform him or her of the processing of personal data concerning him or her, and of the completion of the operations for admissibility and verification of the alert to which he or she has been the subject.

This information, which must be provided within a reasonable period of time that may not exceed one (1) month from the date of receipt of the alert or from the adoption of precautionary measures, specifies the entity responsible for recording the personal data, the facts complained of, the departments to which the alert is addressed and the procedures for exercising the right of access and rectification. The SGD Pharma Group guarantees that any person identified as part of the whistleblowing Procedure has the right to access personal data concerning him or her, and to request its rectification or deletion if it is inaccurate, incomplete, ambiguous or out-of-date.

In this context, the legal requirements for protecting the identity of the Alert Issuer must be observed.

5. Collecting and handling internal alerts

5.1. Triggering an internal alert

The alert may be reported either during a face-to-face and/or videoconference meeting, or in writing, or by voice mail, anonymously or not, at the option of the Alert Issuer. In all cases, the gathering and processing of the alert will be confidential. The Alert Issuer provides all facts, information and/or documents of which he/she is aware and which he/she has, whatever their medium or form, likely to support his/her alert.

Whistleblowing procedures	Alert contact point
Mode 1. Contact your manager or line manager	Manager or line manager

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

<p>Mode 2. Contact the Group by post or by email</p>	<p>SGD PHARMA</p> <p>Liberty Tower</p> <p>17 Place des Reflets</p> <p>92097 Paris La Défense Cedex - France</p> <p>Group HR Director</p> <p>Group General Counsel</p> <p>For Germany (SGD Kipfenberg and SGD Germany GmbH): HR manager</p> <p>For India (SGD Pharma India and SGD Corning Technologies): Managing Director</p>
<p>Mode 3. Alert, either in writing or by voice mail, anonymously</p>	<p>In writing:</p> <p>Whistleblower reporting channel to the team in charge of the "whistleblower" system, accessible via the following link:</p> <p>https://report.whistleb.com/sgdpharma</p> <p>The team responsible for receiving and managing alerts via the "whistleblower" system is composed of the following persons:</p> <ul style="list-style-type: none"> • Group HR Director • Group General Counsel • Group Compliance Officer • Deputy Ethics and Compliance Manager • Chief Financial Officer • West BU General Manager <p>Orally via a hotline:</p> <p>Code for reporting to SGD Pharma Group: 4899#</p> <p>Brazil: 0-800-591-2078</p> <p>China: 400-120-3520</p> <p>France: 0800-916095</p> <p>Germany: 0800-1810898</p>

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

	<p>India: 000800-1009230</p> <p>Italy: 800-789930</p> <p>Portugal: 800-831524</p> <p>Spain: 900-833826</p> <p>United States: 1800-218-8954</p> <p>These reporting channels are administered by WhistleB from NAVEX, an external service provider. All messages are encrypted. To ensure the anonymity of the Issuer, WhistleB does not record IP addresses or other metadata. The issuer of the message also remains anonymous, if desired, during the dialogue with the company's or organization's investigation team.</p>
--	--

All alerts received are treated confidentially.

SGD Pharma recommends that you submit your internal alert via the dedicated platform (mode 3).

5.2. Investigation Procedure

Alerts received via modes 1 and 2 are forwarded by their recipient to the team in charge of alert management and investigation, for instruction and/or information.

Alerts received via mode 3 are processed as follows:

Access to messages received via the alert channel is restricted to designated individuals responsible for managing and investigating alerts. Their actions are traced in the event log, and processing is confidential.

- The team in charge of alert management and investigation is made up of the following persons:
 - Group HR Director (Compliance Committee Member)
 - Group General Counsel (Compliance Committee Member)
 - Chief Financial Officer (Compliance Committee Member)
 - West BU General Manager (Compliance Committee Member)
 - Group Compliance Officer (Compliance Committee Member)
 - Deputy Ethics and Compliance Manager

Discussions and decisions are kept confidential and reported to the CEO if necessary. Decisions with regard to an alert are taken by Compliance Committee Members. In this regard, the legal provisions regarding the confidentiality of the identity of the Alert Issuer and other people concerned will be observed.

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

In accordance with its Ethics and Compliance Guide, and in order to ensure compliance with laws and regulations, notably in the fight against corruption, SGD Pharma Group has set up a Compliance Committee, whose members, by virtue of their qualifications and functions, present all the guarantees of impartiality and competence necessary to the exercise of this mission, namely the management and investigation of alert cases.

- Informing the Alert Issuer

The Alert Issuer must receive an acknowledgement of receipt of his alert within 7 working days.

Once the alert has been received, the team in charge of alert management checks whether the alert is admissible, i.e. whether the conditions set out in articles 2 and 3 of the Procedure have been met and if it is plausible. If further information is necessary to evaluate the beforementioned, the team in charge of alert management will collect this information. For this purpose, it also contacts the Alert Issuer, if this is possible.

If the alert is valid and plausible, appropriate investigative measures are implemented.

The team in charge of alert management may decide not to proceed with the alert if:

- ✓ the behavior complained of is not such as to give rise to an alert, especially if the reported facts are not subject to the scope of application of this Procedure;
- ✓ the message was not written in good faith;
- ✓ there is not enough information to conduct an investigation;
- ✓ the subject of the message has already been processed.

The team in charge of alert management (or one of its members) provides the Alert Issuer with written information on the measures planned or taken to assess the accuracy of the allegations, and the reasons for these measures. This communication shall be made within a period not exceeding 3 months from acknowledgement of receipt of the alert or, in the absence of acknowledgement, 3 months from the expiry of a period of 7 working days following the alert. In this regard, the rights and interests of the persons who are subject to the Alert or are named in it must be observed.

Alerts sent anonymously will continue to be tracked using the login and password that the Alert Issuer received at the end of the alert submission process on the external service provider's platform.

If the alert is accepted, the team in charge of alert management must take appropriate steps to investigate it.

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

5.3. Survey

All messages are treated seriously and confidentially.

- ✓ All persons taking part in an investigation (including internal or external experts when necessary) will respect this principle of seriousness and confidentiality, particularly with regard to the identity of the Alert Issuer.
- ✓ No one taking part in an investigation should seek to identify the Alert Issuer if he/she has chosen to remain anonymous.
- ✓ The team in charge of alert management may, if necessary, submit follow-up questions, via the communication channel and/or by contacting the Alert Issuer directly if the latter has not sent its alert via the said channel.
- ✓ The investigation of an alert will never be entrusted to a person likely to be involved in, or linked to, the alert.
- ✓ Alert messages are treated as confidential by the parties concerned.
- ✓ The participation of internal or external experts in the investigation will require the consent of the Alert Issuer if the information disclosed to them is such as to enable the latter to be identified. All persons who have access to personal data will also be required to respect the confidentiality and anonymity of the Alert Issuer.
- ✓ The investigation team shall also provide the Alert Issuer with written information on the measures planned or taken to remedy the subject of the alert and the reasons for such measures within a reasonable period of time. In this regard, the rights and interests of the person(s) who is/are subject to the Alert or is/are named in it or is/are affected by the measures must be observed.

6. Protecting whistleblowers

6.1. A person who reports a suspicion or concern in good faith must not face the risk of losing his or her job or suffering any form of repression or personal disadvantage.

If they meet all the conditions for whistleblower status, they benefit from a whistleblower protection scheme.

6.2. If the information reported are covered by an obligation of secrecy protected by law, the Alert Issuer will not be held liable for breach of secrecy, subject to compliance with the following conditions:

- He/she meets all the criteria of the whistleblower definition
- Disclosure of a secret is necessary and proportionate to safeguard the interests at stake
- The disclosure of a secret is carried out in compliance with the whistle-blowing Procedure.
- Disclosure does not concern a fact covered by medical secrecy, national defense secrecy or attorney-client privilege.
- Obtaining the information as such or access to the information as such does not constitute an independent criminal offence of the Alert Issuer.

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

6.3. The exercise of the right to alert may not be a reason for an employer or future employer or any other person to:

- To exclude from a recruitment Procedure, from access to an internship or a period of professional training;
- Sanction or dismiss;
- Act in a discriminatory manner, directly or indirectly, in particular with regard to remuneration, profit-sharing measures or the distribution of shares, training, reclassification, assignment, qualification, classification, professional promotion, transfer or contract renewal.

6.4. Can also benefit from a special protection:

- Facilitators (natural persons or non-profit private law legal entities assisting an Alert Issuer in making an alert or disclosure (for example, a colleague, the Works Council, associations, or trade unions), notably against the loss of their job, retaliatory or discriminatory measures or any other damage to their reputation. This protection may also concern the prohibition of termination of contracts for goods and services with an external provider;
- Individuals in connection with an Alert Issuer (for example, a relative) at risk of being the subject of a retaliation measure in the context of their own professional activities from their employer, client or recipient of their services;
- legal entities controlled, within the meaning of Article L. 233-3 of the French Commercial Code, by an Alert Issuer, or for which he or she works, or with which he or she is linked in a professional context.

7. Processing of personal data

7.1 Purpose of processing

As part of the implementation of the whistleblowing system, the SGD Pharma group, through the company SGD SA in charge of processing, may collect personal data (hereinafter the "Data") on:

- the person involved in an alert,
- the Alert Issuer (if not sent anonymously) and,
- any third parties involved.

This Data is processed in order to investigate facts relating to reported breaches and inappropriate behavior under our Code of Ethics and Conduct, our internal rules or facts relating to information listed in article 2.

All processing is carried out in accordance with the applicable regulations, in particular Regulation EU 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of individuals with regard to the processing of personal data and on the free movement of such Data (the "GDPR").

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

7.2. Persons responsible for processing

SGD S.A., Liberty Tower - 17 Place des Reflets - 92097 Paris La Défense Cedex - France, is responsible for the Data processed as part of the whistleblowing service.

WhistleB Whistleblowing Centre Ab (World Trade Centre, Klarabergsviadukten 70, SE-107 24 Stockholm) acts as a subcontractor for the processing carried out by the data controller in the NAVEX WhistleB tool reserved for ethical whistleblowing, including the processing of encrypted data, such as whistleblowing messages. Neither WhistleB nor its subcontractors can decrypt or read alert messages. Therefore, neither WhistleB nor its subcontractors have access to plaintext content.

7.3. Categories of Data Processed

The Data likely to be collected as part of the professional alert system covered by this Procedure are as follows:

- Identity, functions and contact details of the Issuer of the Alert (if the Issuer chooses not to remain anonymous);
- Identity, functions and contact details of persons subject to an alert;
- Identity, functions and contact details of persons involved in receiving or handling the alert;
- The data contained in the description of the facts reported or in the information gathered during the alert and other information gathered as part of the internal investigation.

7.4. Legal basis for processing

Data will only be processed by the SGD Pharma Group through SGD SA, the company in charge of processing, in the event of one of the following cases provided for by the regulations in force:

- to comply with its legal obligations, as specified in this Procedure; or
- when processing is in the SGD Pharma Group's legitimate interest.

7.5. Confidentiality and Data Recipients

Alerts may be made anonymously. In all cases, identifying Data is treated as confidential within the framework of the legal requirements.

Access to Data is strictly limited to authorized persons and to the extent necessary to process alerts.

The persons who may have access to this Data are:

- Alert recipient(s);
- Persons responsible for implementing the investigation Procedure;
- People who may become informed of the alert in accordance with clause 5.3.

These persons only have access to the Data strictly necessary for the processing of the alert.

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

Certain information contained in an alert may be transmitted by the SGD Pharma group to public authorities or competent prosecution authorities, if there is a legal obligation to make such a communication.

7.6. Transfer of data outside the European Union

Except on an exceptional basis to meet the purposes set out in this Procedure (for example, to meet the needs of investigation), the SGD Pharma group does not transfer the Data processed as part of the processing of alerts outside the European Union.

In the event of the need to transfer Data outside the European Union, in particular in the event of an internal investigation with an international dimension, SGD Pharma undertakes to carry out such transfers to countries whose level of protection of personal data has been deemed sufficient by an adequacy decision of the European Commission or to enter into prior specific agreements containing safeguard clauses and appropriate guarantees for the protection of Data such as the standard contractual clauses approved by the European Commission.

Where applicable, Data processing carried out by the SGD Pharma Group through SGD SA complies with the regulations applicable in the country where the group is established.

7.7. Data retention

The SGD Pharma Group retains the Data collected in the context of alert processing to the extent necessary to achieve the aforementioned purposes and in compliance with local laws and regulations and/or local data protection authorities' recommendations applicable in the country where the group processing entity is established.

Accordingly, unless otherwise stipulated by law or regulation, the SGD Pharma Group retains data collected as part of the processing of the alerts at least for the time necessary to analyze the alert and conduct investigations on the reported facts.

The SGD Pharma Group may retain Data for longer periods, including for the following purposes:

- in the event of a legal obligation incumbent on SGD Pharma (e.g. to meet its accounting, social or tax obligations);
- when disciplinary or litigation proceedings are initiated against a person implicated in the whistleblowing Procedure, for evidential purposes, until the end of the proceedings or the limitation period for appeals against the decision taken;
- for the purposes of carrying out quality audits of the procedures implemented for processing alerts.

Anonymized data i.e., data that can no longer be linked to one or more identified or identifiable individuals, may be kept without time limitation.

When retention of the Data is no longer justified pursuant to the present article, SGD Pharma Group suppresses or anonymizes the Data.

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

7.8. Data subjects' rights to their Data

Any person concerned by the processing of his or her Data within the framework of this Procedure has the right to ask the SGD Pharma Group, to the extent permitted by law:

- which Data is processed, for what purposes and in what manner;
- a copy of its Data ;
- Data correction ;
- the deletion of the Data or the limitation of its processing, in the event that i) SGD Pharma no longer requires the information for the purposes for which it was obtained or ii) the use of the Data is contrary to law;
- Data portability, under certain conditions.

Requests to exercise your rights may be sent to the following address:
DataProtection@sgdgroup.com.

Depending on their jurisdiction, data subjects may also file a complaint with the competent data protection authority in their country. In France, the competent authority is the Commission Nationale de l'Informatique et des Libertés (CNIL), which can be contacted at the following address:

<https://www.cnil.fr>

or

3 Place de Fontenoy - TSA 80715 - 75334 Paris - Cedex 07

7.9. Data security

The SGD Pharma Group takes all necessary precautions to protect Data against loss, unauthorized access, modification, intrusion, alteration, disclosure or destruction.

To this end, the SGD Pharma Group implements technical and organizational measures specifically designed to protect Data, including user access control, traceability of actions on Data, software protection (antivirus, security updates and patches, tests, etc.), encryption and physical security procedures.

In addition, the SGD Pharma Group requires its subcontractors to comply with strict security and information protection standards.

8. External alert and list of authorities responsible for external alert

The Alert Issuer has two freely selectable reporting channels:

- an internal alert channel (in accordance with this Procedure); and
- an external alert channel to the relevant authorities.

There is no hierarchy between these two channels. The Alert Issuer can therefore choose to launch an external alert after having initiated an internal alert, or independently of it.

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

The Alert Issuer may therefore apply the external procedure without first having recourse to the internal whistleblowing Procedure.

The external entities to which the external alert can be addressed are listed in:

- Appendix 1 for France
- Appendix 2 for Germany

9. Distribution and advertising

The full whistleblowing Procedure is available on the SGD Pharma Group intranet in the Compliance section.

This Procedure is subject to advertising formalities in accordance with the local regulations applicable to each establishment/company of the SGD Pharma Group.

Versions :

- *Date of coming into force: 27 November 2023 (Initial version)*
- *Revised version N°1: 1st October 2024*
Changes:
 - *Use of the term “Procedure” instead of “Policy” to designate this document*
 - *Addition of a reference to applicable Indian legislation governing vigil mechanism in India*
 - *Addition for BU India of the Managing Director as local contact for Mode 2 of contact (See Paragraph 5.1)*
 - *Addition of the Group Compliance Officer for management and investigation of alerts*
- *Revised version N°2: 1st March 2026*
Changes:
 - *Appointment of the Group Compliance Officer as a member of the Compliance Committee*
 - *Addition of the Group Compliance Lawyer for management and investigation of alerts*
- *Revised version n°3: 1st August 2026*
Changes:
 - *The “Group Compliance Lawyer” title is modified as “Deputy Ethics and Compliance Manager” for the management and investigations of alerts*
 - *Addition of Tracfin as an external competent authority to receive alerts related to financial services, products and markets and the prevention of money laundering and terrorist financing*

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

APPENDIX 1

The external entities to which the external alert can be addressed in France are as follows:

- The *Défenseur des droits* (French Defender of Rights): <https://www.defenseurdesdroits.fr/fr/nous-contacter>
- Judicial authority;
- A European Union institution, body or agency competent to collect information on violations falling within the scope of Directive (EU) 2019/1937 of the European Parliament and of the Council of October 23, 2019;
- A competent authority from among those listed below and by the decree of October 3, 2022. The contact details and list of competent authorities are up to date at the date of publication of this appendix.

1. Public procurement	
<i>Agence française anti-corruption (AFA)</i> (French Anti-Corruption Agency), for breaches of probity	https://www.agencefrancaise-anticorruption.gouv.fr
<i>Direction générale de la concurrence, de la consommation et de la répression des fraudes (DGCCRF)</i> (French Directorate General for Competition Policy, Consumer Affairs and Fraud Control), for anti-competitive practices	https://www.economie.gouv.fr/contact/contacter-la-dgccrf
<i>Autorité de la concurrence</i> (French Competition Authority), for anti-competitive practices	https://www.autoritedelaconcurrence.fr/fr/contact
2. Financial services, products and markets and the prevention of money laundering and terrorist financing	
<i>Autorité des marchés financiers (AMF)</i> (French Financial Market Authority)	https://www.amf-france.org/fr/lanceur-dalerte
<i>Autorité de contrôle prudentiel et de résolution (ACPR)</i> (French Prudential Supervision and Resolution Authority)	https://acpr.banque-france.fr/lacpr/presentation/contacts
<i>Service à compétence nationale Traitement du renseignement et de l'action contre les circuits financiers clandestins (Tracfin)</i> (Intelligence Processing and Action against Clandestine Financial Circuits)	https://demarche.numerique.gouv.fr/commencer/signalement-lanceur-d-alerte-tracfin

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

3. Product safety and conformity	
<i>Direction générale de la concurrence, de la consommation et de la répression des fraudes (DGCCRF)</i> (French Directorate General for Competition Policy, Consumer Affairs and Fraud Control)	https://www.economie.gouv.fr/contact/contacter-la-dgccrf
<i>Service central des armes et explosifs (SCAE)</i> (French Central Arms and Explosives Service)	https://www.interieur.gouv.fr/Infos-du-site/Nous-contacter
4. Transport safety	
<i>Direction générale de l'aviation civile (DGAC)</i> (French Civil Aviation Authority), for air transport safety	https://www.ecologie.gouv.fr/contact-mtes
<i>Bureau d'enquêtes sur les accidents de transport terrestre (BEA-TT)</i> (French Land Transport Accident Investigation Bureau), for land transport safety (road and rail)	https://www.bea-tt.developpement-durable.gouv.fr/spip.php?page=contact
<i>Direction générale des affaires maritimes, de la pêche et de l'aquaculture (DGAMPA)</i> (French Directorate-General for Maritime Affairs, Fisheries and Aquaculture), for maritime transport safety	https://contact.mer.gouv.fr/
5. Environmental protection	
<i>Inspection générale de l'environnement et du développement durable (IGEDD)</i> (French General Inspectorate for the Environment and Sustainable Development)	https://www.igedd.developpement-durable.gouv.fr/spip.php?page=contact
6. Radiation protection and nuclear safety	
<i>Autorité de sûreté nucléaire (ASN)</i> (French Nuclear Safety Authority)	https://www.asn.fr/espace-professionnels/signalement
7. Food safety	
<i>Conseil général de l'alimentation, de l'agriculture et des espaces ruraux (CGAAER)</i> (French High Council for Food, Agriculture and Rural Areas)	https://agriculture.gouv.fr/questions-frequentes-contacts
<i>Agence nationale chargée de la sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)</i>	https://www.anses.fr/fr/content/foire-aux-questions-contact

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

(French Agency for Food, Environmental and Occupational Health and Safety)	
8. Public health	
<i>Agence nationale chargée de la sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)</i> (French Agency for Food, Environmental and Occupational Health and Safety)	https://www.anses.fr/fr/content/foire-aux-questions-contact
Agence nationale de santé publique (Santé publique France, SpF) (French National Public Health Agency)	https://www.santepubliquefrance.fr/nous-contacter
<i>Haute Autorité de Santé (HAS)</i> (French National Authority for Health)	https://www.has-sante.fr/jcms/c_432678/fr/contacter-la-has
<i>Agence de la biomédecine</i> (French Biomedicine Agency)	https://www.agence-biomedecine.fr/Nous-contacter?lang=fr
<i>Etablissement français du sang (EFS)</i> (French Blood Establishment)	https://dondesang.efs.sante.fr/nous-contacter
<i>Comité d'indemnisation des victimes des essais nucléaires (CIVEN)</i> (French Compensation Committee for Victims of Nuclear Tests)	https://www.gouvernement.fr/contact/contacter-le-civen
<i>Inspection générale des affaires sociales (IGAS)</i> (French General Inspectorate of Social Affairs)	https://www.igas.gouv.fr/spip.php?article1
<i>Institut national de la santé et de la recherche médicale (INSERM)</i> (French National Institute of Health and Medical Research)	https://www.inserm.fr/contact/
<i>Conseil national de l'ordre des Médecins</i> (French National Medical Council), for the practice of medicine	https://www.conseil-national.medecin.fr .
<i>Conseil national de l'ordre des masseurs-kinésithérapeutes</i> (French National Council of the Order of Physiotherapists), for the practice of the profession of physiotherapist	https://www.ordremk.fr/ordre/nous-contacter/

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

<i>Conseil national de l'ordre des sages-femmes</i> (French National Council of the Order of Midwives), for the practice of midwifery	https://www.ordre-sages-femmes.fr/informations/contact/
<i>Conseil national de l'ordre des pharmaciens</i> (French National Council of the Chamber of Pharmacists), for the practice of the profession of pharmacist	https://www.ordre.pharmacien.fr/contacter-l-ordre
<i>Conseil national de l'ordre des infirmiers</i> (French National Council of the Order of Nurses), for the practice of the nursing profession	https://www.ordre-infirmiers.fr/contact.html
<i>Conseil national de l'ordre des chirurgiens-dentistes</i> (French National Council of the Order of Dental Surgeons), for the practice of the profession of dental surgeon	https://www.ordre-chirurgiens-dentistes.fr/nous-contacter/
<i>Conseil national de l'ordre des pédicures-podologues</i> (French National Council of the Order of Chiropodists), for the practice of the profession of chiropodist	https://www.onpp.fr/contact.html
9. Consumer protection	
<i>Direction générale de la concurrence, de la consommation et de la répression des fraudes (DGCCRF)</i> (French Directorate General for Competition Policy, Consumer Affairs and Fraud Control)	https://www.economie.gouv.fr/contact/contacter-la-dgccrf
10. Protection of privacy and personal data, network and information systems security	
<i>Commission nationale de l'informatique et des libertés (CNIL)</i> (French Data Protection Authority)	https://www.cnil.fr/fr/lanceurs-dalerte-adresser-une-alerte-la-cnil https://www.cnil.fr/fr/plaintes
<i>Agence nationale de la sécurité des systèmes d'information (ANSSI)</i> (French National Agency for the Security of Information Systems)	https://www.ssi.gouv.fr/agence/contacts/hotel-national-des-invalides/
11. Violations affecting the financial interests of the European Union	

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

<i>Agence française anti-corruption (AFA)</i> (French Anti-Corruption Agency), for breaches of probity	https://www.agence-francaise-anticorruption.gouv.fr/fr/form/signalement
<i>Direction générale des finances publiques (DGFIP)</i> (French Public Finances Directorate General), for value-added tax fraud	https://www.impots.gouv.fr/contacts
<i>Direction générale des douanes et droits indirects (DGDDI)</i> (French Directorate-General of Customs and Indirect Taxes), for fraud involving customs duties, anti-dumping duties and the like	https://www.douane.gouv.fr/engagements-et-qualite/contacter-la-douane-par-voie-electronique
12. Violations relating to the internal market	
<i>Direction générale de la concurrence, de la consommation et de la répression des fraudes (DGCCRF)</i> (French Directorate General for Competition Policy, Consumer Affairs and Fraud Control), for anti-competitive practices	https://www.economie.gouv.fr/contact/contacter-la-dgccrf
<i>Autorité de la concurrence</i> (French Competition Authority), for anti-competitive practices and state aids	https://www.autoritedelaconcurrence.fr/fr/contact
<i>Direction générale des finances publiques (DGFIP)</i> (French Public Finances Directorate General), for corporate tax fraud	https://www.impots.gouv.fr/contacts
13. Activities conducted by the Ministry of Defense	
<i>Contrôle général des armées (CGA)</i> (French General Inspection of the French Armed Forces)	cga.courrier.fct@intradef.gouv.fr
<i>Collège des inspecteurs généraux des armées</i> (French Collège of Inspectors General of the Armed Forces)	https://lannuaire.service-public.fr/gouvernement/b40df350-421d-4424-b581-cfe3d3da6226
14. Public statistics	
<i>Autorité de la statistique publique (ASP)</i> (French Official Statistical Authority)	https://www.autorite-statistique-publique.fr/contacts/

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

15. Agriculture	
<i>Conseil général de l'alimentation, de l'agriculture et des espaces ruraux (CGAAER)</i> (French High Council for Food, Agriculture and Rural Areas)	https://agriculture.gouv.fr/questions-frequentes-contacts
16. Education and higher education	
<i>Médiateur de l'éducation nationale et de l'enseignement supérieur</i> (French Mediator for National Education and Higher Education)	https://www.education.gouv.fr/contacter-la-mediatrice-de-l-education-nationale-et-de-l-enseignement-superieur-et-les-mediateurs-10559
17. Individual and collective labor relations, working conditions	
<i>Direction Générale du travail (DGT)</i> (French Directorate-General for Labor)	https://travail-emploi.gouv.fr/ministere/article/nous-contacter
18. Employment and vocational training	
<i>Délégation générale à l'emploi et à la formation professionnelle (DGEFP)</i> (French General Delegation for Employment and Vocational Training)	https://travail-emploi.gouv.fr/ministere/article/nous-contacter
19. Culture	
<i>Conseil national de l'ordre des architectes</i> (French National Council of the Order of Architects), for the practice of architecture	https://www.architectes.org/information-de-contact
<i>Conseil des maisons de vente</i> (French Auction Market Authority), for public auctions	https://www.conseildesventes.fr/fr/formulaire-de-contact
20. Rights and freedoms in relations with State administrations, local authorities, public establishments and organizations entrusted with a public service mission 21. Best interests of the child 22. Discrimination 23. Ethics of security personnel	
<i>Défenseur des droits</i> (French Defender of Rights)	https://www.defenseurdesdroits.fr/fr/nous-contacter

SGD PHARMA GROUP WHISTLEBLOWING PROCEDURE

APPENDIX 2

The external entities to which the external alert can be addressed in Germany are as follows:

- The Federal Office of Justice (<https://www.bundesjustizamt.de>)
- The Federal Financial Supervisory Authority (https://www.bafin.de/DE/DieBaFin/Hinweisgeberstelle/hinweisgeberstelle_node.html)
- The Federal Cartel Office (https://www.bundeskartellamt.de/DE/Kartellverbot/Anonyme_Hinweise/anonymehinweise_node.html)

An external alert can also be addressed to the following European Union entities:

- The Commission
- The European Anti-Fraud Office (https://anti-fraud.ec.europa.eu/olaf-and-you/report-fraud_de)
- The European Maritime Safety Agency (<https://www.emsa.europa.eu>)
- The European Union Aviation Safety Agency (<http://www.easa.europa.eu>)
- The European Securities and Market Authority (<https://www.esma.europa.eu>) und
- The European Medicines Agency (<https://www.ema.europa.eu>)